Xuanfei Baidu granule
PreclinicalSmall molecule
Xuanfei Baidu granule is one of 49 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
PD-1/PD-L1 Inhibitors
CChuangzhen Chen
Preclinical
Fluvirin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Influenza1 trial
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A
Unknown status·—·N/A·NCT06205641·584 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xuanfei Baidu granule. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details